Brief: Elicera Therapeutics Completes Phase I Part Of Carma Study
12/10/2026 12:36
BRIEF-Elicera Therapeutics Completes Phase I Part Of Carma Study Oct 12 (Reuters) - Elicera Therapeutics AB ELIC.ST:
ELICERA THERAPEUTICS COMPLETES PHASE I PART OF CARMA STUDY OF ELC-301 AND REPORTS COMPLETE METABOLIC RESPONSE IN 8 OF 12 PATIENTS
67% OF PATIENTS ACHIEVE COMPLETE METABOLIC RESPONSE IN PHASE I CARMA STUDY
Source text: ID:nWkr96pf5d
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application